TD Cowen Maintains Buy on Calumet, Raises Price Target to $27

Benzinga · 10/17 17:08
TD Cowen analyst Jason Gabelman maintains Calumet (NASDAQ:CLMT) with a Buy and raises the price target from $22 to $27.